If you’ve opened your Demat account this week, scrolled through your trading app, and suddenly seen the Aequs IPO oversubscribed stamp glowing like a Diwali discount banner — you’re not alone.
IPO season in India often feels like sale season: everybody wants in, everyone’s talking about it, and before you blink, retail quotas start filling up faster than Virat Kohli’s fan seats.
Aequs IPO is the latest name creating that buzz.
On Day 2, the IPO is already 4.44 times subscribed, showing strong interest from retail investors and HNIs — even before institutions go heavy.
But here’s the real question you’re probably asking:
👉 Is the Aequs IPO worth applying for? Or is it another hype wave that may or may not give listing gains?
This blog isn’t a dry recap of numbers. You’ll get:
- A human-friendly breakdown
- 100% original explanation
- Deep insights simplified for the intelligent, curious investor
- Zero jargon
- Practical takeaways
Let’s break it down like two friends talking over chai about where to safely put money.
📌 Aequs IPO Subscription Status: What The 4.44x Oversubscription Really Means
(Primary Keyword Used Naturally)
By 10:30 AM on Day 2 (December 4), investors had placed bids for 18.63 crore shares, despite only a fraction actually being available.
Breakup of Subscription (so far):
- QIB (Institutional Investors): 0.67x subscribed
- NII (HNI Investors): 5.08x subscribed
- Retail (RII): 14.46x subscribed
Retail demand is crazy strong — nearly 14.5 times more bids than shares.
What Does This Reveal?
- Retail investors are treating this as a potential listing-gain candidate.
- HNIs (especially sNII) are aggressively taking leveraged positions.
- QIBs entering slowly means institutions might get active later — typical pattern.
Quick Analogy:
Think about IPL auctions. When multiple teams raise the paddle at the same time for one player… prices shoot up. Here, “bids” are the paddles.
If Day 2 looks like this, Day 3 could cross 20–30x overall.
🧠 What You Should Remember
Oversubscription alone doesn’t guarantee returns. It only shows demand, not valuation fairness. A strong retail rush can also be herd behaviour.
📌 Aequs IPO Details: Price Band, Lot Size, Dates & What They Mean for You
This is where most retail investors make mistakes. Many people just see the issue size and price band — but every tiny detail tells a story.
Let’s simplify.
💰 Aequs IPO Price Band
- ₹118 to ₹124 per share
At the upper band (₹124), the minimum application value becomes:
➡️ ₹14,880 per retail lot (120 shares)
For regular middle-class investors, this fits neatly into the “comfortable risk” zone.
📦 Lot Size & Minimum Application
- Retail lot: 120 shares
- sNII lot: 1,680 shares (14 lots)
- bNII lot: 8,160 shares (68 lots)
This shows the company wants genuine institutional participation and serious HNI commitment.
📅 Key Aequs IPO Dates
- Subscription Window: Dec 3 to Dec 5
- Allotment: Dec 8
- Refunds: Dec 9
- Demat Credit: Dec 9
- Listing Date: Dec 10
If you’ve applied, set reminders. These dates matter if you want to exit quickly or assess gains.
📊 IPO Structure
Total issue size: ₹921.81 crore
Breakup:
✔️ Fresh Issue
- ₹670 crore (5.40 crore shares)
This money likely goes toward:
- Aerospace manufacturing capacity
- Automation
- High-precision engineering facilities
- Working capital
✔️ OFS (Offer for Sale)
- ₹251.81 crore
- 2.03 crore shares offloaded by promoters including:
- Aravind Shivaputrappa Melligeri
- Aequs Manufacturing Investments
- Melligeri Private Family Foundation
- The Melligeri Foundation
OFS doesn’t benefit the company — only the promoters.
So pay more attention to the fresh issue and what the company aims to build.
🧠 What You Should Remember
IPO money must add business value. Fresh issue = growth potential. OFS = promoter exit. Both influence long-term stock performance.
📌 Aequs Limited: What Does the Company Even Do? And Why Are Investors Interested?
Incorporated in 2000, Aequs Ltd operates in one of the most complex, premium, and tech-heavy sectors: Aerospace manufacturing.
This isn’t a “generic manufacturing” company. It creates precision components that literally go into the:
- Engine systems
- Landing gear
- Cargo systems
- Cabin interiors
- Structures and assemblies
This is Tier-1 level Aero supply chain, which significantly narrows competition.
✈️ Why Aerospace Manufacturing Matters (Especially in India 2025)
Aerospace is:
- High-margin
- High-entry-barrier
- Dependent on long-term contracts
- Rarely saturated
Global giants like Boeing and Airbus are increasing outsourcing to India — partly due to cost and partly geopolitical diversification.
So a company like Aequs sits at the right intersection of:
Make in India + Defence + Aerospace + Precision Manufacturing Boom
And this explains why the IPO sentiment is strong.
🧠 What You Should Remember
Companies in aerospace don’t grow at the speed of FMCG—but they often grow steadier, backed by long multi-year contracts.
📌 Should You Apply for Aequs IPO? Honest, Human Analysis
Let’s keep it simple and relatable.
👍 Strengths
- High-entry-barrier industry
- First-mover advantage in India’s precision aerospace manufacturing ecosystem
- Strong retail demand (14.46x)
- Proven track record of complex engineering
- Predictable order books (aerospace contracts are long-term)
👎 Risks
- Aerospace demand depends heavily on global travel industry
- Valuations need careful comparison with peers
- OFS portion suggests partial promoter exit
- QIB participation is lukewarm so far
Real-World Analogy:
Buying into a company like Aequs is like sponsoring an engineering topper for a long-term NASA project — the payoff can be excellent, but you need to wait.
🎯 Verdict for Retail Investors
If you’re looking for:
- Short-term listing gains → Moderate to High possibility
- Long-term investment → Needs deeper financial study, but sector prospects are solid
Risk level: Moderate
🧠 What You Should Remember
Apply if you have risk appetite and understand sector cycles. Avoid if you want guaranteed returns.
📌 Bonus: How Aequs IPO Compares to Corona Remedies IPO (Also Opening This Month)
Many investors are confused between the two.
Here’s a quick, clean comparison table:
| Feature | Aequs IPO | Corona Remedies IPO |
|---|---|---|
| Sector | Aerospace Manufacturing | Pharma & Healthcare |
| Issue Type | Fresh Issue + OFS | 100% OFS |
| Issue Size | ₹921.81 Cr | ₹655.37 Cr |
| Price Band | ₹118–124 | ₹1008–1062 |
| Retail Lot | ₹14,880 | ₹14,868 |
| Subscription Window | Dec 3 – 5 | Till Dec 10 |
| Strength | High-entry-barrier aerospace | Strong pharma brand |
| Risk | Sector cyclicality | Entirely OFS |
Which Should You Choose?
- Want listing gains → Aequs is trending better
- Want stable long-term sector → Pharma (Corona Remedies) is safer
- Want cheaper valuation entry → Aequs
🧠 What You Should Remember
Both IPOs serve different investor mindsets. Pick based on your risk appetite, not hype.
📌 Final Thoughts
IPO investing is like choosing a startup internship in college — do you want the fast-paced, risky ride or the stable, predictable job?
Aequs IPO is gaining serious traction, especially from retail and HNIs. The aerospace sector is promising, India’s defence manufacturing push is real, and global demand is returning.
But remember: over-subscription reflects interest, not guaranteed profits.
If you’re applying, apply with clarity — not FOMO.